Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

After 1:1 propensity score matching, baseline characteristics were well balanced: age, sex, race, and ethnicity were comparable between groups; the prevalence of major comorbidities, including hypertension, diabetes, ischemic heart disease, and cerebrovascular disease, was similar; and the distribution of medication use (ACE inhibitors, angiotensin II inhibitors, vitamin D, calcium channel blockers, bisphosphonates, calcium, GLP-1 analogues, and DPP-4 inhibitors) was nearly identical.

Source: Study Population. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a retrospective multicenter cohort study using the TriNetX research network (2010-2024).

Source: Abstract.

Eligible patients were adults with end-stage renal disease (ESRD) who subsequently developed severe secondary hyperparathyroidism (SHPT), defined as the presence of at least one documented intact parathyroid hormone (iPTH) measurement exceeding 600 pg/mL.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Expanding Outcomes Beyond Chronic Kidney Disease-Mineral and Bone Disorder: A Propensity Score-Matched Analysis of Parathyroidectomy versus Calcimimetics in Dialysis Patients with Secondary Hyperparathyroidism

Cohort study · International Journal of Medical Sciences · 2026

Original publication title

Expanding Outcomes Beyond Chronic Kidney Disease-Mineral and Bone Disorder: A Propensity Score-Matched Analysis of Parathyroidectomy versus Calcimimetics in Dialysis Patients with Secondary Hyperparathyroidism

Yi-Chou Hou; Cai-Mei Zheng; Ko-Lin Kuo; Kuo-Wang Tsai; Joshua Wang; Cheng-Yi Wang; Ruei-Ming Chen; Kuo-Cheng Lu

© The author(s)

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In patients with ESRD and severe SHPT, parathyroidectomy was associated with lower risks of mortality, mild cognitive impairment, and sepsis compared with calcimimetic therapy, while cardiovascular and fracture outcomes were comparable. These findings suggest that PTx may confer broader systemic benefits beyond mineral and bone disorder control in selected dialysis patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Secondary hyperparathyroidism (SHPT) is a common complication in patients with end-stage renal disease (ESRD) receiving dialysis. Although calcimimetics (CAMs) and parathyroidectomy (PTx) are widely used for severe SHPT, their comparative effects on long-term clinical outcomes beyond mineral and bone disorder remain uncertain.

Source: Background

Abstract: What methods does the paper describe?

We conducted a retrospective multicenter cohort study using the TriNetX research network (2010-2024). Adult dialysis patients with ESRD and severe SHPT, defined by at least one historical intact parathyroid hormone level >600 pg/mL prior to treatment initiation, were included. Patients receiving both therapies were excluded. After 1:1 propensity score matching for demographics, comorbidities, medications, and laboratory variables, outcomes including all-cause mortality, major adverse cardiovascular events (MACE), fracture, cognitive impairment, mild cognitive impairment (MCI), and sepsis were compared using Cox proportional hazards models.

Source: Methods

Abstract: Results

After propensity score matching, 22,580 patients were included (11,290 in each group), with follow-up extending to 7 years. Compared with CAM therapy, PTx was associated with significantly lower risks of all-cause mortality (hazard ratio [HR] 0.914, 95% confidence interval [CI] 0.860-0.972), mild cognitive impairment (HR 0.646, 95% CI 0.436-0.955), and sepsis (HR 0.844, 95% CI 0.765-0.930). No significant differences were observed for MACE, fracture, hungry bone disease, overall cognitive impairment, or malignancy.

Source: Results

Abstract: Conclusion

In patients with ESRD and severe SHPT, parathyroidectomy was associated with lower risks of mortality, mild cognitive impairment, and sepsis compared with calcimimetic therapy, while cardiovascular and fracture outcomes were comparable. These findings suggest that PTx may confer broader systemic benefits beyond mineral and bone disorder control in selected dialysis patients.

Source: Conclusion
Authors’ abstract

Background

Secondary hyperparathyroidism (SHPT) is a common complication in patients with end-stage renal disease (ESRD) receiving dialysis. Although calcimimetics (CAMs) and parathyroidectomy (PTx) are widely used for severe SHPT, their comparative effects on long-term clinical outcomes beyond mineral and bone disorder remain uncertain.

Methods

We conducted a retrospective multicenter cohort study using the TriNetX research network (2010-2024). Adult dialysis patients with ESRD and severe SHPT, defined by at least one historical intact parathyroid hormone level >600 pg/mL prior to treatment initiation, were included. Patients receiving both therapies were excluded. After 1:1 propensity score matching for demographics, comorbidities, medications, and laboratory variables, outcomes including all-cause mortality, major adverse cardiovascular events (MACE), fracture, cognitive impairment, mild cognitive impairment (MCI), and sepsis were compared using Cox proportional hazards models.

Results

After propensity score matching, 22,580 patients were included (11,290 in each group), with follow-up extending to 7 years. Compared with CAM therapy, PTx was associated with significantly lower risks of all-cause mortality (hazard ratio [HR] 0.914, 95% confidence interval [CI] 0.860-0.972), mild cognitive impairment (HR 0.646, 95% CI 0.436-0.955), and sepsis (HR 0.844, 95% CI 0.765-0.930). No significant differences were observed for MACE, fracture, hungry bone disease, overall cognitive impairment, or malignancy.

Conclusion

In patients with ESRD and severe SHPT, parathyroidectomy was associated with lower risks of mortality, mild cognitive impairment, and sepsis compared with calcimimetic therapy, while cardiovascular and fracture outcomes were comparable. These findings suggest that PTx may confer broader systemic benefits beyond mineral and bone disorder control in selected dialysis patients.

Publication and source details

Original title: Expanding Outcomes Beyond Chronic Kidney Disease-Mineral and Bone Disorder: A Propensity Score-Matched Analysis of Parathyroidectomy versus Calcimimetics in Dialysis Patients with Secondary Hyperparathyroidism

Yi-Chou Hou; Cai-Mei Zheng; Ko-Lin Kuo; Kuo-Wang Tsai; Joshua Wang; Cheng-Yi Wang; Ruei-Ming Chen; Kuo-Cheng Lu

International Journal of Medical Sciences · 2026

✉ Corresponding author: Kuo-Cheng Lu, MD, Professor, Division of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 289 Jianguo Road, New Taipei City 23142, Taiwan, Email: kuochenglu@gmail.com, Phone: +886266289779.

Competing Interests: The authors have declared that no competing interest exists.

© The author(s)2026https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See https://ivyspring.com/terms for full terms and conditions.This study was supported by grants from the MOST (110-2314-B-038 -075: MY3) and Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (TCRD-TPE-110-02(2/3) and TCRD-TPE-111-01(3/3)) and Cardinal Tien Hospital (CTH-114-AK-NDMC-2231).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:27:56.660116+00:00

DOI: 10.7150/ijms.131653 · PMC13280741